Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift

被引:42
作者
Chatzidionysiou, Katerina [1 ,2 ]
Sfikakis, Petros P. [1 ,2 ]
机构
[1] Natl & Kapodistrian Univ Athens, Dept Propaedeut & Internal Med 1, Sch Med, Laikon Hosp, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Joined Rheumatol Program, Sch Med, Laikon Hosp, Athens, Greece
来源
RMD OPEN | 2019年 / 5卷 / 02期
关键词
ADALIMUMAB PLUS METHOTREXATE; LOW DISEASE-ACTIVITY; TREAT-TO-TARGET; DOUBLE-BLIND; ANTIRHEUMATIC DRUGS; NAIVE PATIENTS; COMBINATION; THERAPY; MULTICENTER; MANAGEMENT;
D O I
10.1136/rmdopen-2019-000993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment of rheumatoid arthritis (RA) has improved substantially during the last decades, mainly due to the development and introduction in everyday practice of new, highly efficacious, disease-modifying antirheumatic drugs (DMARDs), more optimal usage of them, earlier diagnosis and tighter control of disease activity targeting at remission. Methotrexate is still today the anchor drug and the first-line treatment after diagnosis. However, numerous studies comparing methotrexate and biologic DMARDs, as well as new targeted synthetic DMARDs, both in early as in more established disease, have shown consistently better efficacy of the latter compared with methotrexate, with methotrexate yielding remission to maximum half of patients. This could suggest a new paradigm shift with earlier start of a biologic or a targeted synthetic DMARD, with the possibility of subsequent discontinuation in case of achievement of stable remission. Several strategy trials, however, have shown that there might be a clinical and structural benefit of initial, aggressive therapy, possibly even associated with higher chance of remaining in remission, after cessation of the biologic DMARD and continuing with methotrexate alone, but they have failed to show a clear advantage of such an aggressive treatment strategy. This might become a valuable option for the future treatment algorithm of RA, especially for a subgroup of patients with RA, but further confirmation from future research is needed. The crucial role of glucocorticoid use as part of the combination strategy should be acknowledged, and strategy trials should include this combination as an active comparator.
引用
收藏
页数:6
相关论文
共 35 条
[1]  
Allaart CF, 2007, J RHEUMATOL, V34, P25
[2]   Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial [J].
Bijlsma, Johannes W. J. ;
Welsing, Paco M. J. ;
Woodworth, Thasia G. ;
Middelink, Leonie M. ;
Petho-Schramm, Attila ;
Bernasconi, Corrado ;
Borm, Michelle E. A. ;
Wortel, Cornelis H. ;
ter Borg, Evert Jan ;
Jahangier, Z. Nazira ;
van der Laan, Willemijn H. ;
Bruyn, George A. W. ;
Baudoin, Paul ;
Wijngaarden, Siska ;
Vos, Petra A. J. M. ;
Bos, Reinhard ;
Starmans, Mirian J. F. ;
Griep, Eduard N. ;
Griep-Wentink, Joanna R. M. ;
Allaart, Cornelia F. ;
Heurkens, Anton H. M. ;
Teitsma, Xavier M. ;
Tekstra, Janneke ;
Marijnissen, Anne Carien A. ;
Lafeber, Floris P. J. ;
Jacobs, Johannes W. G. .
LANCET, 2016, 388 (10042) :343-355
[3]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[4]   Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial [J].
Burmester, Gerd R. ;
Rigby, William F. ;
van Vollenhoven, Ronald F. ;
Kay, Jonathan ;
Rubbert-Roth, Andrea ;
Kelman, Ariella ;
Dimonaco, Sophie ;
Mitchell, Nina .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (06) :1081-1091
[5]   Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].
Clair, EWS ;
van der Heijde, DMFM ;
Smolen, JS ;
Maini, RN ;
Bathon, JM ;
Emery, P ;
Keystone, E ;
Schiff, M ;
Kalden, JR ;
Wang, B ;
DeWoody, K ;
Weiss, R ;
Baker, D .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443
[6]   2016 update of the EULAR recommendations for the management of early arthritis [J].
Combe, Bernard ;
Landewe, Robert ;
Daien, Claire I. ;
Hua, Charlotte ;
Aletaha, Daniel ;
Alvaro-Gracia, Jose Maria ;
Bakkers, Margot ;
Brodin, Nina ;
Burmester, Gerd R. ;
Codreanu, Catalin ;
Conway, Richard ;
Dougados, Maxime ;
Emery, Paul ;
Ferraccioli, Gianfranco ;
Fonseca, Joao ;
Raza, Karim ;
Silva-Fernandez, Lucia ;
Smolen, Josef S. ;
Skingle, Diana ;
Szekanecz, Zoltan ;
Kvien, Tore K. ;
van der Helm-van Mil, Annette ;
van Vollenhoven, Ronald .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) :948-959
[7]   Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study [J].
Detert, Jacqueline ;
Bastian, Hans ;
Listing, Joachim ;
Weiss, Anja ;
Wassenberg, Siegfried ;
Liebhaber, Anke ;
Rockwitz, Karin ;
Alten, Rieke ;
Krueger, Klaus ;
Rau, Rolf ;
Simon, Christina ;
Gremmelsbacher, Eva ;
Braun, Tanja ;
Marsmann, Bettina ;
Hoehne-Zimmer, Vera ;
Egerer, Karl ;
Buttgereit, Frank ;
Burmester, Gerd-R .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (06) :844-850
[8]   Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials [J].
Emamikia, Sharzad ;
Arkema, Elizabeth V. ;
Gyori, Noemi ;
Detert, Jacqueline ;
Chatzidionysiou, Katerina ;
Dougados, Maxime ;
Burmester, Gerd Ruediger ;
van Vollenhoven, Ronald .
RMD OPEN, 2016, 2 (02)
[9]   Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study [J].
Emery, P. ;
Bingham, C. O., III ;
Burmester, G. R. ;
Bykerk, V. P. ;
Furst, D. E. ;
Mariette, X. ;
van der Heijde, D. ;
van Vollenhoven, R. ;
Arendt, C. ;
Mountian, I. ;
Purcaru, O. ;
Tatla, D. ;
VanLunen, B. ;
Weinblatt, M. E. .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :96-104
[10]   Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial [J].
Emery, Paul ;
Breedveld, Ferdinand C. ;
Hall, Stephen ;
Durez, Patrick ;
Chang, David J. ;
Robertson, Deborah ;
Singh, Amitabh ;
Pedersen, Ronald D. ;
Koenig, Andrew S. ;
Freundlich, Bruce .
LANCET, 2008, 372 (9636) :375-382